Nascent Biotech, Inc. (OTCMKTS:NBIO – Get Free Report)’s stock price crossed above its fifty day moving average during trading on Tuesday . The stock has a fifty day moving average of $0.00 and traded as high as $0.0004. Nascent Biotech shares last traded at $0.0004, with a volume of 1,000 shares traded.
Nascent Biotech Stock Performance
About Nascent Biotech
Nascent Biotech, Inc, a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of various forms of cancer. It is developing Pritumumab, a drug to treat patients with brain cancer malignancies, such as glioblastoma and malignant astrocytoma, as well as epithelial cancers, including lung, breast, colon, brain, and pancreas cancer. The company is developing MultiPharm, a proprietary technology platform for cancer therapy, as well as diabetes, autoimmunity, and transplantation.
Read More
- Five stocks we like better than Nascent Biotech
- Fifth Third’s Big Bet Is On
- Dell’s AI Toll Bridge Is Paved with Record Margins
- As AI Data Breaches Become More Common, This Cybersecurity ETF Is SurgingAI
- Coke’s $10B India IPO Plan Pops the Top on Hidden Value
Receive News & Ratings for Nascent Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nascent Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
